Immune Repertoire Sequencing Market Size, Share and Trends Analysis, By Product and Services (Instruments, Reagents & Kits, Software & Bioinformatics, and Services), By Sequencing Type (Bulk, Single Cell, and Long Cell), By Cell Type (B-Cell Repertoire and T-Cell Repertoire), By Application, By End-Use, and By Region, Forecast 2026-2033

Immune Repertoire Sequencing Market Overview and Key Insights:

Immune repertoire sequencing market size reached USD 343.8 Million in 2025 and is expected to register a revenue CAGR of 9.2% during the forecast period. IR-Seq uses next-generation sequencing (NGS) to characterize the variety of B-cell receptors (BCRs) and T-cell receptors. IR-Seq allows researchers to analyse repertoire diversity and clonality, as well as look into receptor sequences linked to haematological malignancies, autoimmune diseases, and other illnesses.

Market Drivers:

Growing adoption in immunotherapy development is a key driver driving the market revenue growth. Each mature lymphocyte in the repertoire is unique in its uniqueness and is referred to as ‘clonal’. Because T-cell and B-cell lymphocytes are constantly scanning the body for antigens from external bodies, they go through a process analogous to natural selection. Understanding the immunological repertoire is critical in the era of precision medicine and immunotherapy, where medicines are being created to be more effective for everyone. There are numerous immune-system-affecting medicines in development and usage. Measuring the immunological repertoire may aid in the prediction of therapy outcomes and can be used to monitor treatment effects. Treatments for increasing the immunological repertoire are also being developed, such as the use of cytokines as medicines.

Immune repertoire sequencing is best achieved through targeted amplicon-based sequencing. Targeted sequencing also provides a chance to explore the immunological repertoire using RNA. Targeted RNA sequencing allows access to more genetic material and has a direct correlation with clonal genetic information. This allows for the sequencing of genetic material in peripheral blood, enabling liquid biopsy applications.

On July 2025, Immunai Grand launched a collaboration initiative for single cell immune profiling. Through this project, selected researchers will have simple access to cutting-edge single cell multi-omic immunological sequencing. Data created will be returned to researchers for further analysis and publishing, while also increasing AMICA, a growing resource that aids discovery in immunology and pharmaceutical research and development.

Market Opportunity:

AI-driven platforms & cloud solutions and integration with multi-omics & digital biomarkers demand acts as opportunities for immune repertoire sequencing market. Recent breakthroughs in machine learning (ML), a branch of artificial intelligence, have considerably improved the analysis of multiomics datasets. Unsupervised methods, such as autoencoders, reduce dimensionality and extract features, while supervised algorithms—such as gradient boosting machines and neural networks—construct predictive and descriptive models from large-scale biological data, enabling a clearer understanding of complex immune interactions.

These models are increasingly being used to predict B-cell and T-cell epitopes, assess vaccine candidates, and identify immunological receptor specificities from genomic, proteomic, and immune repertoire sequencing data. Deep learning has enabled the extraction of meaningful patterns from high-dimensional immunological sequencing data, with applications in cancer vaccine formulation and infectious disease diagnostics.

Recent Trends:

Emerging trends include single-cell immune repertoire profiling, development of clinical-grade assays, automation & high-throughput workflows, long-read sequencing for full V(D)J resolution, and AI/ML-based clonotype annotation & prediction.

Advancements in high-throughput sequencing methods have now made it possible to sequence the genetic diversity of the immune repertoire and identify the specific sequences involved in an immune response. Sequencers capable of producing several reads long enough to span entire immune regions are now available from Illumina, PacBio, and Oxford Nanopore. A wide range of laboratory approaches have been developed for T-cell and B-cell receptor library preparation for these sequencing platforms.

Moreover, recent breakthroughs in ab initio protein structure prediction from amino acid sequences—such as those enabled by the AlphaFold Protein Structure Database have accelerated the prediction of antibody structures. Tools like IgFold, developed by researchers at Johns Hopkins University, are expanding the ability to accurately connect immune repertoire sequences with their corresponding targets.

On December 2023, Carterra Inc., the global leader in label-free high-throughput antibody discovery and development, and ENPICOM B.V. have announced a collaboration to improve the analysis of rapidly rising sequencing and antibody screening data generated in the lab. ENPICOM’s IGX Platform enables researchers to manage, analyze, and visualize immune repertoire data. The platform excels in integrating various sequencing datasets, as well as experimental data and metadata. The increased adoption of high-throughput repertoire sequencing (Rep-Seq) in antibody discovery campaigns in recent years has resulted in considerably more promising therapeutic candidates to investigate, moving from a library of hundreds to millions.

Restraints & Challenges:

One significant problem in immune repertoire sequencing is effectively capturing the structural and sequence complexity of antibodies and TCR genes during library preparation and bioinformatic analysis. Furthermore, the lack of conventional reference controls complicates measuring sequencing accuracy and sensitivity. Sequencing technologies exacerbate these issues. Accurate short reads cannot span these complex features, whereas noisy lengthy reads may cause artifacts and need more input data, limiting their usefulness. BCR sequencing data are based on complex biological systems. It is difficult to appropriately evaluate the biological significance of sequencing results based on the function, immune response, and disease state of B cells.

Product and Services Segment Insights and Analysis:

Based on the product and services, immune repertoire sequencing market is segmented into instruments, reagents & kits, software & bioinformatics, and services.

Instruments segment contributed the largest market share in 2025. It is further sub segmented into Next-Generation Sequencers (NGS), single-cell sequencing platforms, long-read sequencers, and integrated immune profiling systems. High throughput sequencing technology is an effective technique for identifying immune system composition alterations induced by infectious illnesses. IR-seq can provide detailed insights into antibody responses to vaccination and pathogen stimulation, both of which modify the repertoire of naive immune receptors. Therefore, numerous studies have attempted to dissect adaptive immune receptor repertoire following antigen challenge. The pre-existing immunity related to antigens exposure history has an important impact on antibody response to vaccines.

Researchers can find out why older people are more susceptible to infection and have trouble reacting to immunizations by using IR-seq. Immune repertoire sequencing has emerged as a successful technique for infectious illness diagnosis, prognosis, and vaccine development. The immune diversity is age-dependent, indicating that immunologic function declines with increasing age.

On May 2024, Parse Biosciences, a leading provider of user-friendly and scalable single cell sequencing solutions, has announced the release of Evercode BCR and the expansion of its existing Evercode TCR product line. The new BCR solution and upgrades to the existing TCR product line broaden Parse’s single cell portfolio, allowing researchers to explore the immune repertoire with unparalleled resolution and scale.

Cell Type Segment Insights and Analysis:

Based on the cell type, immune repertoire sequencing market is segmented into B-cell repertoire and T-cell repertoire.

B-cell repertoire segment contributed the largest market share in 2025. B cell receptor sequencing (BCR-seq) is an advanced and rapid method for detecting all target-amplified B-cell receptors (BCRs) by combining high-throughput sequencing technology and bioinformatics. By analyzing the quantity of each nucleotide, BCR-seq reveals the complexities of B-cell-mediated humoral immune responses as well as the dynamic diversity of immunoglobulin changes. This cutting-edge technology allows for a complete investigation of the fundamental mechanisms that govern the immune system’s ability to respond and adapt, paving the way for a more in-depth understanding of immune system dynamics.

BCR sequencing is a powerful tool for digging into the complexities of disease pathophysiology, allowing for early surveillance and diagnosis. It is critical in assessing tumor homology within an organism, hence improving understanding of cancer biology and progression. It makes it easier to screen for somatic cell mutations, especially in patients with primary immunodeficiencies like isolated IgA deficiency, allowing for more tailored medicinal interventions.

Application Segment Insights and Analysis:

Based on the application, immune repertoire sequencing market is segmented into immunotherapy development, infectious disease research, oncology, autoimmune disease characterization, transplantation monitoring, and others.

Oncology segment contributed the largest market share in 2025. According to the American Cancer Society, in 2026, the US is projected to have 2.1 million new cancer diagnoses (excluding non-melanoma skin cancers) and about 626,000 deaths. In 2026, cancer will affect around 9,680 children (ages 0-14) and 5,660 adolescents (ages 15-19), with 1,090 children and 730 adolescents dying from the disease. Cancer is the greatest cause of death among children and adolescents.

Advances in high-throughput sequencing tools now allow for the sequencing of the immune repertoire’s genetic variety as well as the identification of specific sequences implicated in immunological responses. T-cell clones that target tumor antigens can be identified by profiling the TCR repertoire of tumor-infiltrating lymphocytes (TILs). This data can then be utilized to create T-cell-based immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapy, that target and kill cancer cells. TCR sequencing can potentially be used to assess treatment response and identify potential tumor immune escape pathways.

Geographical Outlook:

Immune repertoire sequencing market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Immune Repertoire Sequencing Market:

North America is registered to have highest market share in immune repertoire sequencing market in 2025. This is mainly driven by growing adoption in immunotherapy development, rising demand for precision medicine, and rising prevalence of chronic diseases. Traditionally, immune repertoire profiling depended on cloning, Sanger sequencing, or functional approaches to determine antigen specificity (e.g., tetramer assays/stains). Although these methodologies have provided useful insights, the ongoing development of next-generation sequencing (NGS) has significantly increased the scope of repertoire profiling research. Sequencing mRNA exposes the sequence of expressed receptors that have undergone splicing and post-transcriptional processing, increasing the likelihood of functional protein production.

On September 2025, Illumina Inc. has announced the availability of Illumina Protein Prep, an assay that provides enhanced performance for next-generation sequencing (NGS)-based proteomics discovery at scale. Illumina Protein Prep was initially available through an early-access program and is now widely available to customers worldwide, allowing researchers to incorporate proteomics into large-scale genomics studies and fuel new insights across cancer, cardio metabolic, and immunologic diseases, with a streamlined sample-to-insights solution for discovery and clinical research.

Asia Pacific Immune Repertoire Sequencing Market:

Asia Pacific is expected to register the fastest growth rate during the forecasted period, driven by expanding genomics infrastructure, rising prevalence of cancer and autoimmune disorders, and increasing adoption of precision medicine. Countries such as China, Japan, South Korea, and India are heavily investing in NGS capabilities and large-scale population genomics initiatives, which directly support immune repertoire sequencing research and clinical applications. India is witnessing growing adoption due to cost-effective sequencing services, expanding CRO activity, and increasing clinical research collaborations.

On April 2023, leading life science data and digital solutions provider Excelra has purchased BISC Global, a bioinformatics and data analytics consulting firm with operations in the USA and Europe. With proficiency in artificial intelligence, machine learning, omics, and next-generation sequencing data processing, the purchase establishes a global leader in consulting-led bioinformatics. Additionally, it provides next-generation platforms like ImmunoRaptor, an analysis platform that facilitates the management and analysis of immune repertoire sequencing data, and the Online Pipeline Platform (OP2), which supports streamlined analysis of bulk RNA-seq, single-cell RNA-seq, somatic variant calling, and germline variant calling data.

Competition Analysis:

Immune repertoire sequencing market is characterized by a consolidated structure, with few players competing across various segments and regions. List of major players included in immune repertoire sequencing market report are:

• Illumina, Inc.
• CD Genomics
• Thermo Fisher Scientific Inc.
• BGI Genomics Co., Ltd.
• iRepertoire, Inc.
• Miltenyi Biotec
• QIAGEN
• Adaptive Biotechnologies
• New England Biolabs
• Alacris Theranostics GmbH
• Integrated DNA Technologies, Inc.
• Synbio Technologies
• ENPICOM
• Signios Bio
• Celemics, Inc.

Strategic Developments in Immune Repertoire Sequencing Market:

• In January 2026, Parse Biosciences, the leading provider of accessible and scalable single cell sequencing technology, has announced the addition of a fully integrated immune repertoire and whole transcriptome analysis approach to its data analysis platform, Trailmaker. The new functionality complements Parse’s existing Evercode immune product portfolio, allowing researchers to complete a full end-to-end workflow. The new Trailmaker functionality directly tackles these issues by offering an accessible, end-to-end immune profiling solution that integrates repertoire and transcriptional data in a single context.
• In May 2025, Etcembly has inked a collaborative agreement with DJS Antibodies, a division of AbbVie, to speed the discovery of new antibody therapies. Etcembly’s flagship AI platform, EMLy, is the most advanced immune discovery and engineering technology. EMLy combines billions of T-cell receptor (TCR) and antibody sequences with cutting-edge bioinformatics, large language models (LLMs), and structural modeling to allow for unparalleled research of immune system interactions with targets.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2023 to 2024, with 2025 serving as the base year for market size calculations. The forecast period extends from 2026 to 2033.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of Immune Repertoire Sequencing Market Report:

Immune Repertoire Sequencing market report offers a detailed analysis of market size, including historical revenue (in USD Million) data for 2023-2024 and revenue forecasts for 2026-2033 across the following segments:

• Product and Services Outlook (Revenue, USD Million; 2023-2033)
  • Instruments
    • Next-Generation Sequencers (NGS)
    • Single-Cell Sequencing Platforms
    • Long-Read Sequencers
    • Integrated Immune Profiling Systems
  • Reagents & Kits
  • Software & Bioinformatics
  • Services
    • Sequencing Services
    • Data Interpretation & Reporting
    • Custom Assay Development

• Sequencing Type Outlook (Revenue, USD Million; 2023-2033)
  • Bulk Immune Repertoire Sequencing
  • Single-Cell Immune Repertoire Sequencing
  • Long-Read Immune Repertoire Sequencing

• Cell Type Outlook (Revenue, USD Million; 2023-2033)
• • B-Cell Repertoire
  • T-Cell Repertoire

• Application Outlook (Revenue, USD Million; 2023-2033)
  • Immunotherapy Development
  • Infectious Disease Research
  • Oncology
  • Autoimmune Disease Characterization
  • Transplantation Monitoring
  • Others

• End-Use Outlook (Revenue, USD Million; 2023-2033)
  • Biopharmaceutical & Vaccine Companies
  • Academic & Research Institutions
  • Contract Research Organizations (CROs) / CDMOs
  • Clinical & Diagnostic Laboratories
  • Government & Public Health Agencies

• Regional Outlook (Revenue, USD Million; 2023-2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about Immune Repertoire Sequencing market report